Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $18.7 million.

  • Insight Molecular Diagnostics' Cash & Equivalents rose 45000.0% to $18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.7 million, marking a year-over-year increase of 45000.0%. This contributed to the annual value of $8.6 million for FY2024, which is 843.94% down from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Cash & Equivalents stood at $18.7 million for Q3 2025, which was up 45000.0% from $24.3 million recorded in Q2 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' Cash & Equivalents peaked at $58.9 million during Q1 2021, and registered a low of $3.4 million during Q3 2024.
  • Its 5-year average for Cash & Equivalents is $23.3 million, with a median of $20.0 million in 2022.
  • As far as peak fluctuations go, Insight Molecular Diagnostics' Cash & Equivalents crashed by 7536.23% in 2024, and later surged by 45408.93% in 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' Cash & Equivalents (Quarter) stood at $32.9 million in 2021, then crashed by 39.32% to $20.0 million in 2022, then crashed by 52.82% to $9.4 million in 2023, then decreased by 8.44% to $8.6 million in 2024, then soared by 116.54% to $18.7 million in 2025.
  • Its last three reported values are $18.7 million in Q3 2025, $24.3 million for Q2 2025, and $31.0 million during Q1 2025.